NCT03341936 2025-06-18Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHNDana-Farber Cancer InstitutePhase 2 Active not recruiting29 enrolled 11 charts
NCT03347123 2022-02-28A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)Incyte CorporationPhase 1/2 Terminated11 enrolled 12 charts